Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from NEJM

HIV prevention medication ‘could one day be a yearly jab’ – study suggests

Yearly doses could reduce barriers people face to taking preventative HIV medication, researchers said.

Evening Standard

Designer immune-cell therapy could shrink deadly brain tumors, early trials show

Two early clinical trials that together included nine patients suggest that a treatment called CAR-T therapy could treat glioblastoma, but its long-term effects are unknown.

LiveScience

The growing case for doing less: How harmless cancers are being overdiagnosed in America

The pattern extends to multiple cancers, including those affecting the breast, prostate, melanoma, and thyroid.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Could an antibiotic taken after unprotected sex prevent STIs? What to know about doxy-PEP.

This summer, the CDC is expected to release guidelines for the use of doxy-PEP to prevent STIs. But what is it, and why is everyone talking about it now?

LiveScience

13 horrific firework injuries that will keep you cautious on July 4

As July Fourth celebrations take off across the U.S., so will the number of firework-related accidents and hospital visits.

LiveScience

The truth about MSG, a much-maligned source of great flavour

Is MSG the cause of an allergy? Is it a public menace? If so - and the bulk of evidence says it isn't - it's many foods you eat every day.

The New Daily

New Alzheimer's drug shows modest slowing of early disease progression

Scientists are cautiously optimistic about the promise of an experimental drug shown to modestly slow the progression of Alzheimer's disease in some patients.

ABC News

Read news from The Economist, FT, and more,
with one subscription

Newly identified Langya virus tracked after China reports dozens of cases

Virus, which causes symptoms including fever, fatigue, cough, loss of appetite and muscle aches, is believed to have spread from animals to humans

The Guardian - AU

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Benzinga

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE:NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021. The NEJM publication includes additional analyses substantiating the longest median…

Benzinga

People

Adam Liaw

19 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

New England Journal of Medicine

the New England Journal of Medicine

JAMA Internal Medicine

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.